Newsletter | January 30, 2025

01.30.25 -- What's The Deal With eConsent?

SPONSOR

Is it time to turn the page on your trial management practices? Join us Feb. 11-13 for Clinical Leader Solutions Expo: Tech Week as experts across EDC, IRT, and eCOA introduce the latest in technologies. We’ll help you discover whether it’s time to write your next chapter and connect you with the partners ready to help you do so – all from the convenience of your computer. Register today and finish your clinical trials story strong.

FEATURED EDITORIAL

What's The Deal With eConsent?

Are you for or against eConsent? It’s odd that this technology has kind of become a polarizing topic in the clinical trials industry. To find out why, I decided to get some feedback from folks who have actually used it. 

INDUSTRY INSIGHTS

7 Key Considerations For Designing The Optimal IRT/RTSM

Sponsors can create IRT/RTSM systems that are not only efficient and reliable but also adaptable to the evolving needs of clinical research by focusing on these seven key considerations.

The Rise Of The Clinical Trial Site Mega Network

Learn about the evolving U.S. clinical trial site market landscape including a detailed analysis of ownership models, market segmentation, and the role of financial investors in acquisitions. 

Site-Centric Clinical Platforms Are Better For Sponsors

Discover how seven of the top 15 global biopharmaceutical companies came together on a single clinical technology platform and operated through common workflows and common trial documents.

Q&A With Novartis And IQVIA Study Start-Up Leaders

The industry is measuring longer cycle times between protocol approval and site activation. Experts from Novartis and IQVIA share creative solutions to combat this trend and accelerate trial timelines.

Fomenting A Culture Of Analytical Excellence In Clinical Development

Building an "analytics culture" in clinical research requires striking a balance between fast, flexible technologies and the right support for trial teams working to integrate these solutions.